tradingkey.logo

Penumbra Inc

PEN

263.120USD

-9.610-3.52%
Close 09/15, 16:00ETQuotes delayed by 15 min
10.25BMarket Cap
69.42P/E TTM

Penumbra Inc

263.120

-9.610-3.52%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated2025-09-12

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
11 / 207
Overall Ranking
99 / 4724
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 20 analysts
Buy
Current Rating
312.588
Target Price
+14.61%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 41.02% year-on-year.
Undervalued
The company’s latest PE is 71.48, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 37.32M shares, decreasing 7.06% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 3.85M shares of this stock.

Financial Health

Currency: USD Updated2025-09-12

The company's current financial score is 7.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.15. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 324.14M, representing a year-over-year increase of 16.32%, while its net profit experienced a year-over-year increase of 256.51%.

Score

Industry at a Glance

Previous score
7.00
Change
0

Financials

5.83

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

7.39

Operational Efficiency

7.52

Growth Potential

7.18

Shareholder Returns

7.10

Company Valuation

Currency: USD Updated2025-09-12

The company’s current valuation score is 4.80, which is higher than the Healthcare Equipment & Supplies industry's average of 2.15. Its current P/E ratio is 69.96, which is 394.96% below the recent high of 346.27 and -24.49% above the recent low of 87.09.

Score

Industry at a Glance

Previous score
4.08
Change
-0.01

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 11/207
No Data

Earnings Forecast

Currency: USD Updated2025-09-12

The company’s current earnings forecast score is 8.32, which is higher than the Healthcare Equipment & Supplies industry's average of 7.66. The average price target for Penumbra Inc is 320.00, with a high of 350.00 and a low of 266.00.

Score

Industry at a Glance

Previous score
8.30
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 20 analysts
Buy
Current Rating
312.588
Target Price
+14.61%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

118
Total
7
Median
8
Average
Company name
Ratings
Analysts
Penumbra Inc
PEN
20
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
29
1
2
3
...
24

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated2025-09-12

The company’s current price momentum score is 9.39, which is higher than the Healthcare Equipment & Supplies industry's average of 7.47. Sideways: Currently, the stock price is trading between the resistance level at 280.19 and the support level at 244.00, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
8.75
Change
-1.34

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(3)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-2.542
Neutral
RSI(14)
48.081
Neutral
STOCH(KDJ)(9,3,3)
19.842
Sell
ATR(14)
8.000
High Vlolatility
CCI(14)
-85.999
Neutral
Williams %R
95.802
Oversold
TRIX(12,20)
0.507
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
274.264
Sell
MA10
275.730
Sell
MA20
268.955
Sell
MA50
251.794
Buy
MA100
261.520
Buy
MA200
262.697
Buy

Institutional Confidence

Currency: USD Updated2025-09-12

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. The latest institutional shareholding proportion is 95.72%, representing a quarter-over-quarter increase of 0.41%. The largest institutional shareholder is The Vanguard, holding a total of 3.85M shares, representing 9.88% of shares outstanding, with 4.09% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Fidelity Management & Research Company LLC
4.95M
+1.88%
The Vanguard Group, Inc.
Star Investors
3.67M
+0.68%
BlackRock Institutional Trust Company, N.A.
3.53M
+0.86%
T. Rowe Price Associates, Inc.
Star Investors
1.18M
-4.73%
State Street Global Advisors (US)
1.20M
-0.46%
Elsesser (Adam)
960.02K
+2.58%
Baillie Gifford & Co.
Star Investors
689.00K
-5.65%
RTW Investments L.P.
862.77K
+0.04%
Fidelity Institutional Asset Management
894.92K
-7.28%
Champlain Investment Partners, LLC
869.92K
-41.85%
1
2

Risk Assessment

Currency: USD Updated2025-09-12

The company's beta value is 0.45. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
5.63
Change
0
Beta vs S&P 500 index
0.42
VaR
+3.89%
240-Day Maximum Drawdown
+25.22%
240-Day Volatility
+41.39%
Return
Best Daily Return
60 days
+11.91%
120 days
+11.91%
5 years
+16.55%
Worst Daily Return
60 days
-5.26%
120 days
-5.26%
5 years
-10.03%
Sharpe Ratio
60 days
+0.68
120 days
-0.01
5 years
+0.31
Risk Assessment
Maximum Drawdown
240 days
+25.22%
3 years
+52.44%
5 years
+62.56%
Return-to-Drawdown Ratio
240 days
+1.68
3 years
+0.37
5 years
+0.09
Skewness
240 days
+1.46
3 years
+0.74
5 years
+0.55
Volatility
Realised Volatility
240 days
+41.39%
5 years
+45.22%
Standardised True Range
240 days
+3.10%
5 years
+3.19%
Downside Risk-Adjusted Return
120 days
-1.82%
240 days
-1.82%
Maximum Daily Upside Volatility
60 days
+32.61%
Maximum Daily Downside Volatility
60 days
+25.92%
Liquidity
Average Turnover Rate
60 days
+1.19%
120 days
+1.28%
5 years
--
Turnover Deviation
20 days
+2.27%
60 days
+8.96%
120 days
+16.98%

Peer Comparison

Healthcare Equipment & Supplies
Penumbra Inc
Penumbra Inc
PEN
7.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
7.87 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
7.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
7.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
7.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Abbott Laboratories
Abbott Laboratories
ABT
7.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI